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Abstract
Introduction: Lafora disease (LD) is a rare form of progressive infantile epilepsy in which rapid neurological de-
terioration occurs as the disease advances, leading the patients to a vegetative state and then death, usually
within the first decade of disease onset. Based on the capacity of the endogenous cannabinoid system (ECS)
to modulate several cellular processes commonly altered in many neurodegenerative processes, as well as
the antiepileptic properties of certain natural cannabinoids, the aim of this study was to evaluate the role of
the ECS in LD progression.
Materials and Methods: We tested whether a natural cannabis extract highly enriched in cannabidiol (CBD) might
be effective in curbing the pathological phenotype of malin knockout (KO) mice as an animal model of LD.
Results: Our results reveal for the first time that alterations in the ECS occur during the evolution of LD, mainly at
the level of CB1, CB2, and G protein-coupled receptor 55 (GPR55) receptor expression, and that a CBD-enriched
extract (CBDext) is able to reduce the cognitive impairment exhibited by malin KO mice. However, in contrast to
what has previously been reported for other kinds of refractory epilepsy in childhood, the CBD-enriched extract
does not reduce the severity of the epileptic seizures induced in this animal model of LD.
Conclusions: In summary, this study reveals that the ECS might play a role in LD and that a CBD-enriched extract
partially reduces the dementia-like phenotype, but not the increased vulnerability to epileptic seizures, exhibited
by an animal model of such a life-threatening disease.
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Introduction
Lafora disease (LD) is a rare, fatal, autosomal recessive
form of infantile progressive myoclonus epilepsy. As
the disease advances, rapid neurological deterioration
occurs, leading to a vegetative state and death, usually
within the first decade of disease onset.1,2 Unfortu-
nately, existing treatments are only palliative and no
curative drugs are available yet.3
The hallmark of LD is the accumulation of insolu-
ble polyglucosan inclusions, called Lafora bodies
(LBs), within not only neurons and astrocytes but
also in heart, muscle, and liver cells.2,4 Recessive mu-
tations in two main loci, EPM2A and EPM2B, are
known to produce LD. EPM2A encodes the glucan
phosphatase laforin; up to 60% of patients present
mutations for this gene. EPM2B encodes E3-ubiquitin
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ligase malin, mutated in 20–30% of patients. Al-
though it is known that the two proteins are involved
in the regulation of glycogen metabolism and form
a functional complex, the underlying molecular mecha-
nisms of this pathology are not fully understood.
The existing animal models of LD are genetically
engineered mice lacking functional EPM2A5 or EPM2B6
genes. Both models exhibit LBs and neuronal degenera-
tion, although the malin model exhibits a more severe
phenotype.6
Abundant scientific evidence shows that the activity
of the endogenous cannabinoid system (ECS) can pro-
tect neurons against a variety of toxic stimuli and mod-
ulate various processes that are commonly altered in
many neurodegenerative processes.7 This modulatory
system is composed of at least two well-characterized
cannabinoid receptors coupled to Gi/o proteins,
namely CB1 and CB2 receptors, their endogenous li-
gands (anandamide and 2-arachidonoylglycerol, main-
ly), and the enzymes associated with the synthesis and
degradation of these endocannabinoid compounds. Can-
nabinoids can also bind to other receptors such as the
G protein-coupled receptor 55 (GPR55), the peroxi-
some proliferator-activated receptors PPARa and
PPARc, and transient receptor potential vanilloid-1
(TRPV1).8
To date, no information is available about the poten-
tial involvement of the ECS in LD onset and progres-
sion. However, considering that this disease shares
several pathological processes that are common to
most neurodegenerative diseases (excitotoxicity, oxida-
tive stress, neuroinflammation, synaptic alterations,
and neuronal death), we hypothesize that the ECS
might play a role in LD and could become a poten-
tial therapeutic target against this neurodegenerative
disorder. Further, the benefit of targeting the ECS in
LD might be extended to a reduction in the incidence
of epileptic seizures, since numerous cannabinoid com-
pounds, especially cannabidiol (CBD), have shown
interesting anticonvulsant properties in refractory in-
fantile epilepsies.9,10 For these reasons, the aim of this
study was to challenge this hypothesis by using malin
knockout (KO) mice as an animal model of LD.
Materials and Methods
Animals
Mice homozygous for the EPM2B deletion6 and their
corresponding wild-type (WT) littermates were used
for the study. Experimental groups were composed
of 6–11 animals. All animal procedures were carried
out by following the guidelines of the European Com-
munities Council Directive 2010/63/EU and with the
approval of the local ethical committee of the Univer-
sity of Barcelona.
Chronic treatment with a CBD-enriched
cannabis extract
Animals were treated 5 days/week for 2 months from
4 months of age (early symptomatic phase) and 10
months of age (advanced symptomatic phase). Each
experimental group received the CBD-enriched natu-
ral cannabis extract (CBDext: 98.5 mg/kg/day, con-
taining 35 mg/kg/day of CBD and 4.8 mg/kg/day of
D9-tetrahydrocannabinol [THC], among other minor
cannabinoids including 2.5 mg/kg/day of cannabigerol
[CBG], 3.3 mg/kg/day of cannabinol [CBN], 2.7 mg/
kg/day of cannabichromene [CBC], 4 mg/kg/day
of cannabidiol acid [CBDA], and <1 lg/kg/day of
D9-tetrahydrocannabinol acid [THCA]) provided by
Hemp Solutions S.L. (Spain) or vehicle (olive oil) by
oral gavage.
The selection of the dose was based on previous
studies reporting anticonvulsant properties of CBD-
enriched extracts in other refractory epilepsies in chil-
dren.10 After 3 days of washing period, animals were
subjected to behavioral evaluation.
Behavioral evaluation
Cognitive performance was evaluated in the two-object
recognition test, as previously described.11 To evaluate
motor function, we quantified spontaneous activity and
motor coordination. Spontaneous locomotor activity
was measured by quantifying the total distance traveled
by the animals during 10 min spent in a slightly illumi-
nated open field (30 cm long · 30 cm wide). Alterations
in motor coordination were evaluated with the coat
hanger test. The apparatus consists of a coat hanger
(30 cm in length, 2 mm diameter) suspended 32 cm
above a padded surface. The fall latency was recorded
as the time from when the animal was attached to
the hanger with its front paws until its fall, with a max-
imum time of 1 min. Each animal was subjected to four
sessions, separated in time by at least 1 h.
At the end of the behavioral testing, animals were
killed and their brains were rapidly removed from
the skull and processed for study. One hemisphere
was dissected on ice, immediately frozen, and stored
at 80C until use. The other hemisphere was fixed
in 4% paraformaldehyde and processed for morpho-
logical studies.






















































During the daily handling of animals over 8 weeks of
chronic treatment, no spontaneous seizures occurred.
However, sporadic seizures were observed in their home
cage in animals older than 15 months. For these reasons,
the potential anticonvulsant properties of the CBDext
were evaluated in malin KO and WT mice aged 16 months
in the pilocarpine-induced seizure model.12
Animals were pretreated with the muscarinic antago-
nist scopolamine (1 mg/kg, s.c.; Sigma-Aldrich) 30 min
before pilocarpine injection to prevent peripheral effects
of the drug, and with the CBDext (98.5 mg/kg, oral) or ve-
hicle 15 min before the administration of a submaximal
dose of pilocarpine (250 mg/kg, i.p., Sigma-Aldrich).
Then, the mice were observed for 1 h and scored according
to this scale: (1) tremor; (2) single myoclonic jerks; (3) clo-
nus; (4) one tonic-clonic seizure; (5) two seizures; (6) three
or more seizures; and (7) death, or status epilepticus.
Quantification of LBs
The LBs were visualized with PAS staining and immu-
nohistochemical techniques. Fixed tissue samples were
embedded in paraffin, and 4-lm coronal sections were
cut with a microtome. De-waxed sections were incu-
bated with 1% periodic acid for 15 min, followed by
an additional 15-min incubation with Schiff reagent.
Sections were lightly counterstained with hematoxylin.
After staining, the sections were dehydrated and cover-
slipped for observation under a Nikon Eclipse E800 mi-
croscope (20 · objective). LB density was calculated as
the percentage of the area of PAS staining with respect
to the total brain area. Pictures of 1 section per case
were taken from the motor and retrospenial cortex,
hippocampus (molecular layer), brainstem, and cere-
bellum, corresponding to the main regions in which
LB deposition is observed in malin KO mice.3
Nissl staining and cell counting
De-waxed sections were stained with 10% cresyl violet
at 56C for 1 h, dehydrated, and cover-slipped for ob-
servation under a Nikon Eclipse E800 microscope
(40 · objective). The cell density in the motor cortex
and CA1 region of the hippocampus was calculated
in one representative picture taken from each animal
by using the Count and Analysis tools of the Adobe
Photoshop CS4 software.
Quantification of gene expression
The gene expression of CB1, CB2, GPR55 cannabinoid
receptors, TRPV1 receptor, endocannabinoid-degrading
enzymes fatty acid amide hydrolase (FAAH), and
monoacylglycerol lipase (MAGL) and several com-
ponents of the inflammatory signaling (the pro-
inflammatory cytokines TNFA, interleukin (IL)-1B,
IL-6, and the markers of microglial and astroglial reac-
tivity IBA1 and GFAP, respectively) were quantified
from frozen sensorimotor cortex and hippocampus
samples of malin KO and WT mice with a quantitative
real-time polymerase chain reaction by using TaqMan
system (Applied Biosystems). Samples were analyzed
with the double delta CT method by using vehicle-
treated WT samples as control and Hprt and Xpnpep1
as house-keeping genes.
Quantification of protein levels
The levels of postsynaptic density protein-95 (PSD-95;
1:500; Invitrogen), synaptophysin (1:4,000; Novocastra),
GFAP (1:500; Dako), and IBA1 (1:1,000; Wako) proteins
were evaluated in the sensorimotor cortex and hippo-
campus of mice by western blotting, as previously de-
scribed.11 Densitometric quantification was carried
out with TotalLab v2.01 software (Pharmacia) by using
b-actin (1:10,000; Abcam) as protein loading control.
Statistical analysis
Statistical analysis was performed with the SPSS Sta-
tistics v21.0 software. Data were analyzed with two-way
analysis of variance (ANOVA) with genotype and
treatment as between factors, followed by Tukey’s
post hoc when required (treated mice), Student’s t-test
(gene expression of ECS components), or Chi-square
test (viability after pilocarpine-induced seizures). In all
the experiments, the significance level was set at p < 0.05.
Results and Discussion
Quantification of the ECS components
in malin KO mice
To assess the potential involvement of the ECS in
LD progression, we evaluated the gene expression levels
of CB1, CB2, GPR55, and TRPV1 receptors, and FAAH
and MAGL endocannabinoid degradative enzymes, in
the sensorimotor cortex and the hippocampus of
malin KO mice at different stages of the neurodegener-
ative process. Our results reveal, for the first time, clear
overexpression of the CB2 receptor in the cortex
( p < 0.05) and the hippocampus ( p < 0.001) of malin
KO mice at 12 months of age (Fig. 1B, D), but no sig-
nificant differences at 6 months of age despite a ten-
dency ( p = 0.07) to increase in the hippocampus
(Fig. 1A), as well as a significant reduction in the expression
of CB1 ( p < 0.01) in the cortex of malin KO mice (Fig. 1D)





















































and a significant increase of GPR55 in the hippocampus of
malin KO mice at 12 months of age (Fig. 1B).
Similar alterations in the two main cannabinoid re-
ceptors were also reported in other neurodegenerative
diseases such as Alzheimer’s disease and Huntington’s
disease.13 According to previous evidence, these changes
in the expression of the main cannabinoid receptors
might reveal a loss of the capacity of CB1 receptor to
protect neurons against toxic stimuli and the participa-
tion of the CB2 receptor in the inflammatory process oc-
curring in LD.14
GPR55 function in the brain is still poorly under-
stood but some previous evidence indicates a relevant
role of this receptor in memory processing, neurogen-
esis, and immune responses in the hippocampus.15,16
Thus, our results revealing increased levels of GPR55
in the hippocampus of malin KO mice at advanced
age suggest a role for this receptor in the progression
of the disease and point GPR55 out as a potential ther-
apeutic target against LD. Other ECS components eval-
uated were not modified in malin KO mice at any of the
ages analyzed.
FIG. 1. Gene expression quantification of the main ECS components (CB1, CB2, GPR55, and TRPV1 receptors,
and the endocannabinoid degradative enzymes FAAH and MAGL) in the hippocampus (upper panels) and
sensorimotor cortex (lower panels) of WT and malin KO mice at 6 months (left panels) or 12 months of age
(right panels). No significant alterations in the expression of any of the ECS components evaluated were
observed in mice at 6 months of age in the hippocampus (A) or in the cortex (B) in spite of a tendency to
increase the expression of the CB2 receptor in the hippocampus of malin KO mice. In contrast, malin KO mice
showed a significant increase in the CB2 receptor expression in the hippocampus (C) and cortex (D), as well as
higher expression of Gpr55 in the hippocampus and reduced expression levels of CB1 receptor in the cortex at
12 months of age. Data are expressed as the mean values – SEM. *p < 0.05, **p < 0.01, ***p < 0.001 compared
with WT. ECS, endogenous cannabinoid system; Cnr1, gene coding for CB1 receptor; Cnr2, gene coding for CB2
receptor; Faah, gene coding for fatty acid amide hydrolase; Gpr55, gene coding for G protein-coupled receptor
55; KO, knockout; Mgll, gene coding for monoacylglycerol lipase; SEM, standard error of the mean; TRPV1, gene
coding for transient receptor potential vanilloid-1; WT, wild-type.





















































FIG. 2. Behavioral evaluation of WT (white bars) and malin KO (black bars) mice after chronic treatment
during 2 months with the CBD-enriched extract (98.5 mg/kg/day, containing 35 mg/kg/day of CBD and 4.8 mg/
kg/day of THC, among other minor cannabinoids) from 4 (left panels) and 10 (right panels) months of age. (A,
B) CBDext reduced the memory impairment of malin KO when administered from 10 months of age but it
induced a reduction of the memory performance in WT aged 4 months at the beginning of treatment. (C, D)
Spontaneous locomotor activity was not significantly modified by treatment or genotype at any age. (E, F)
CBDext was not able to reduce motor coordination impairment of aged malin KO mice in the coat hanger test.
Data are expressed as the mean values – SEM. *p < 0.05, **p < 0.01, p = 0.06 compared with WT. &&p < 0.01






















































Cognitive and motor evaluation of treated
malin KO mice
To challenge whether the cannabinoids might have po-
tential utility in treating this orphan disease, we treated
malin KO mice with a CBD-enriched cannabis extract,
because of the neuroprotective, anti-inflammatory, and
anti-epileptic properties exhibited by this compound
in other animal models and human studies.9,10,17,18
Control malin KO mice exhibited memory impairment
at 6 months (Fig. 2A, p < 0.01) and 12 months of age
(Fig. 2B, p < 0.05) when compared with WT mice, as
revealed by the significant reduction of the recognition
index in the two-object recognition test. Interestingly,
chronic treatment with the CBDext improved the
cognitive performance in aged malin KO mice when
compared with vehicle-treated littermates ( p < 0.01,
Fig. 2B). However, CBDext induced a significant reduc-
tion in the memory performance of WT mice when ad-
ministered from 4 months of age ( p < 0.01, Fig. 2A),
raising questions about the potential side effects of
this natural cannabis extract in healthy animals. This
undesired effect could be related to the D9-THC contents
of the cannabis extract used (4.8 mg/kg/day), but further
research is needed to corroborate this assumption.
As shown in Figure 2C and D, spontaneous locomo-
tor activity measured during 10 min in the open field
was not significantly modified by treatment or genotype
at any age. Motor coordination was evaluated with the
coat hanger test. No significant motor coordination im-
pairment was observed in malin KO mice treated from 4
months of age, despite a tendency to decrease in motor
coordination (Fig. 2E). In contrast, vehicle-treated malin
KO mice aged 10 months at the beginning of the treat-
ment exhibited a significant reduction in their motor co-
ordination, as revealed by the decrease in fall latency
from the coat hanger (Fig. 2F, p < 0.05 compared with
WT mice). However, CBDext was not able to reduce
this motor coordination impairment. Specific details
about the statistical analysis of behavioral evaluation
are included in Table 1.
Neuroprotective and neuroinflammatory properties
of the CBD-enriched extract
We first hypothesized that the distinct cognitive alter-
ations produced by CBDext in WT and malin KO
mice might be associated with the modulation of syn-
aptic plasticity in brain areas that are relevant for
cognition. Because of this, we evaluated the levels of
PSD-95, one of the major scaffolding proteins, in the
excitatory postsynaptic density and a potent regulator
of synaptic strength,19 and the levels of the presynaptic
component synaptophysin in cortical and hippocampal
samples of treated mice.
No significant differences in synaptophysin or PSD-95
protein levels were observed in the hippocampus at any
age (Fig. 3A, B). In contrast, two-way ANOVA revealed
a significant interaction [F(1,10) = 5.515, p < 0.05], but no
genotype or treatment effect, in the levels of PSD-95 in
cortical samples from mice treated from 4 months of
age (Fig. 3C). Subsequent Tukey’s post hoc test showed
a tendency to decrease in PSD-95 levels in CBD-treated
WT mice ( p = 0.06) and to increase in CBD-treated
malin KO mice ( p = 0.08), suggesting that the modula-
tion of PSD-95 might be related to the distinct cognitive
alterations produced by CBDext in both genotypes at
early stages. However, no significant modulation of
PSD-95 levels was observed in mice treated from 10
months of age (Fig. 3D).
Table 1. Statistical Details of the Behavioral Evaluation of Malin Knockout Mice Treated During 8 Weeks from
4 or 10 Months of Age with Cannabidiol-Enriched Extract or Vehicle










Two-way ANOVA (treatment from 4 months of age)
Memory F(1,35) = 5.763, p < 0.05 F(1,35) = 0.612, N.S. F(1,35) = 7.366, p < 0.01 p < 0.01 N.S. p < 0.01 N.S.
Locomotor activity F(1,16) = 0.102, N.S. F(1,16) = 0.041, N.S. F(1,16) = 0.104, N.S. — — — —
Motor coordination F(1,39) = 2.529, N.S. F(1,39) = 0.801, N.S. F(1,39) = 0.523, N.S. — — — —
Two-way ANOVA (treatment from 10 months of age)
Memory F(1,24) = 1.879, N.S. F(1,24) = 2.592, N.S. F(1,24) = 5.226, p < 0.05 p < 0.05 N.S. N.S. p < 0.01
Locomotor activity F(1,25) = 2.347, N.S. F(1,25) = 0.758, N.S. F(1,25) = 0.003, N.S. — — — —
Motor coordination F(1,25) = 9.376, p < 0.01 F(1,25) = 0.017, N.S. F(1,25) = 0.022, N.S. p < 0.05 p = 0.06 — —
Two-way ANOVA with genotype and treatment as between-subjects factors was applied for the analysis of memory performance, locomotor
activity, and motor coordination. When one factor or interaction between factors was significant, comparisons between groups were performed
by Tukey’s post hoc test. See the Materials and Methods section for details.
ANOVA, analysis of variance; CBD, cannabidiol; KO, knockout; N.S., not significant; VEH, vehicle; WT, wild-type.





















































Moreover, a significant interaction [F(1,10) = 13.248,
p < 0.01], but no genotype or treatment effect, was ob-
served in cortical synaptophysin levels of mice treated
from 10 months of age (Fig. 3D). Subsequent Tukey’s
post hoc test revealed a significant decrease in the
synaptophysin levels of vehicle-treated malin KO
( p < 0.05) and of CBD-treated WT mice ( p < 0.01)
when compared with vehicle-treated WT mice (Fig. 3D),
suggesting presynaptic impairment as a substrate for
the cognitive decline in aged animals. Nevertheless,
the CBDext did not significantly modulate synaptophy-
sin levels in treated malin KO mice, which indicates that
other mechanisms must underlie the cognitive im-
provement induced by this cannabis extract at ad-
vanced stages.
Among other potential mechanisms involved in
the memory improvement induced by the CBDext in
malin KO mice, we focused on cellular viability and
FIG. 3. Synaptic density in the hippocampus (upper panels) and sensorimotor cortex (lower panels) of WT
(white bars) and malin KO (black bars) after chronic treatment with VEH or CBD-enriched extract (98.5 mg/kg/
day, containing 35 mg/kg/day of CBD and 4.8 mg/kg/day of THC, among other minor cannabinoids) from 4
months of age (left panels) or from 10 months of age (right panels). (A, B) Representative immunoblots and
densitometry quantification for PSD-95 and synaptophysin (Syn) proteins in the hippocampus of treated mice
revealed no statistical differences between groups at 6 months (A) or 12 months of age (B). (C, D)
Representative immunoblots and densitometry quantification for PSD-95 and synaptophysin (Syn) proteins in
the cortex of treated mice. No significant differences between groups were observed in PSD-95 levels at any age,
despite a tendency to decrease in WT and to increase in malin KO mice treated with CBD-enriched extract from 4
months of age (C). Densitometry quantification of synaptophysin immunoblots revealed no difference due to
genotype and/or treatment in animals treated from 4 months of age (C), but a significant reduction in vehicle
malin KO and CBDext WT mice treated from 10 months of age (D). Data are expressed as mean values – SEM.
*p < 0.05, compared with WT; &&p < 0.01 compared with vehicle. PSD-95, postsynaptic density protein-95.





















































neuroinflammation based on the already known pro-
tective and anti-inflammatory properties of CBD.17,18
Our findings reveal that the CBDext does not halt the
cellular loss occurring in the cortex of malin KO
mice from the early stages of the neurodegenerative
process but it reduces the loss of neurons in the CA1
hippocampal area observed in malin KO mice at 12
months of age, which might contribute to the memory
alterations observed. Specifically, cell counts from Nissl
staining in the motor cortex of animals treated from 4
months of age, but not from 10 months of age, revealed
a significant genotype effect [F(1,22) = 11.621, p < 0.01],
but no treatment effect or interaction between the
two factors. Subsequent Tukey’s post hoc test showed
a reduction in cellular density in the cortex of malin
KO mice, both those treated with vehicle ( p < 0.05)
and those treated with CBDext ( p < 0.05) when com-
pared with WT animals (Fig. 4A, B). No significant dif-
ference due to genotype or treatment was observed on
the cellular density in CA1 area of the hippocampus of
FIG. 4. Quantification of the cellular density in the motor cortex (upper panels) and the CA1 region of the
hippocampus (lower panels) of WT (white bars) and malin KO (black bars) after chronic treatment with VEH or
CBD-enriched extract (CBDext 98.5 mg/kg/day, containing 35 mg/kg/day of CBD and 4.8 mg/kg/day of THC,
among other minor cannabinoids) from 4 months (left panels) or 10 months of age (right panels). (A) Malin KO
mice treated from 4 months of age showed a significant cellular loss in the motor cortex when compared with
WT animals, but no effect of CBDext was revealed. (B) In spite of a tendency, no statistical difference due to
genotype and/or treatment was revealed in the motor cortex of older animals. (C) Cellular density in the CA1
region of the hippocampus was not modified by genotype and/or treatment in animals treated from 4 months
of age. (D) In contrast, malin KO mice treated with CBDext from 10 months of age exhibited a higher cellular
density in the hippocampus than vehicle-treated littermates. Data are expressed as the mean values – SEM.
*p < 0.05, compared with WT; &p < 0.05 compared with VEH.





















































FIG. 5. (A, B) Representative images of LBs in the motor cortex (upper panels) and cerebellum (bottom
panels) of malin KO mice after chronic treatment with vehicle (left panels) or CBD-enriched extract (CBDext:
98.5 mg/kg/day, containing 35 mg/kg/day of CBD and 4.8 mg/kg/day of THC, among other minor cannabinoids,
right panels) from 4 months (A) and 10 months of age (B). Magenta staining indicates LB formation. Nuclei are
counterstained in blue with hematoxylin. Scale bar represents 50 lm. (C, D) LB density quantification in motor
and retrospenial cortex, hippocampus (molecular layer), brainstem, and cerebellum of animals treated from 4
months (C) or 10 months of age (D). Malin KO mice treated with CBDext from 4 months of age exhibited a
reduction in LB density in motor cortex and cerebellum. Data are expressed as the mean values – SEM.






















































mice treated from 4 months of age (Fig. 4C). In con-
trast, a significant interaction [F(1,22) = 4.712, p < 0.05],
but no genotype or treatment effect, was observed in
the density of cells in CA1 area of the hippocampus of
mice treated from 10 months of age (Fig. 4D). Thus,
subsequent Tukey’s post hoc test showed an increase
in cellular density in the hippocampus of CBD-treated
malin KO when compared with vehicle-treated malin
KO mice ( p < 0.05).
Interestingly, the CBDext reduced, when administered
from 4 months of age, the accumulation of neurotoxic
LB in discrete brain areas. Densitometry quantification
of PAS staining revealed a significant decrease in the den-
sity of LB in the motor cortex ( p < 0.05) and cerebellum
FIG. 6. Glial reactivity in the hippocampus (upper panels) and cortex (lower panels) of WT (white bars) and
malin KO (black bars) after chronic treatment with VEH or CBD-enriched extract (CBDext: 98.5 mg/kg/day,
containing 35 mg/kg/day of CBD and 4.8 mg/kg/day of THC, among other minor cannabinoids) from 4 months
of age (left panels) or from 10 months of age (right panels). (A, B) Representative immunoblots and
densitometry quantification for GFAP (astroglial marker, upper band) and IBA1 (microglial marker, middle
band) proteins and corresponding actin (lower band) loading control from hippocampal samples. No
significant alterations in IBA1 or GFAP levels due to treatment or genotype were found in the brain
hippocampus of animals treated from 4 months of age (A). In contrast, a significant increase in the
hippocampal levels of IBA1 and GFAP was observed in malin KO mice treated from 10 months of age when
compared with WT animals (B). (C, D) Representative immunoblots and densitometry quantification for GFAP
(upper band) and IBA1 (middle band) proteins and corresponding actin (lower band) loading control from
cortical samples. No statistical differences between groups were observed in animals treated from 4 months
(C) or 10 months of age (D), despite a tendency to increase GFAP levels in malin KO mice treated from 10
months of age when compared with WT animals. Data are expressed as the mean values – SEM. *p < 0.05,
compared with WT.





















































( p < 0.05) of malin KO mice chronically treated with the
CBDext from 4 months of age (Fig. 5A, C), but not from
10 months of age (Fig. 5B, D). However, the mecha-
nisms underlying this CBDext-induced effect and its con-
tribution to the cognitive improvement observed remain
to be elucidated.
Next, we explored the potential anti-inflammatory
properties of the CBDext in malin KO mice. The pro-
tein levels of astroglial (GFAP) and microglial (IBA1)
reactivity markers were evaluated in sensorimotor
cortical and hippocampal samples by western blotting.
As shown in Figure 6A and C, no significant alterations
in IBA1 or GFAP levels due to treatment or genotype
were found in brain hippocampal or cortical samples
of animals treated from 4 months of age. In contrast, a ge-
notype effect was observed in the levels of IBA1 [Hippo-
campus: F(1,10) = 19.150, p < 0.01; Cortex: F(1,10) = 5.871,
p < 0.05] and GFAP [Hippocampus: F(1,10) = 7.573,
p < 0.05; Cortex: F(1,10) = 8.491, p < 0.05] in the animals
treated from 10 months of age. Tukey’s post hoc test
revealed no significant differences between WT and
malin KO mice treated with vehicle or CBDext in the
FIG. 7. Gene expression of several inflammatory components in the hippocampus (upper panels) and
sensorimotor cortex (lower panels) of WT (white bars) and malin KO (black bars) after chronic treatment with
CBD-enriched extract (CBDext: 98.5 mg/kg/day, containing 35 mg/kg/day of CBD and 4.8 mg/kg/day of THC,
among other minor cannabinoids) from 4 months (left panels) and 10 months of age (right panels). (A, B) Malin
KO mice treated from 4 months of age (A), independently of the treatment received, exhibited increased
expression of the genes coding for GFAP and IL-1b; whereas those treated from 10 months of age (B) expressed
higher levels of all the evaluated inflammatory signaling components than WT mice in the hippocampus. No
effect of treatment was observed in any of the genes analyzed in the hippocampus. (C, D) Similar to what
occurred in the hippocampus, malin KO mice expressed in the cortex higher levels of GFAP than WT mice when
treated from 4 months of age (C) or from 10 months of age (D), as well as increased expression levels of the
IBA1 and the pro-inflammatory cytokines IL-1b, IL-6 and TNF-a coding genes in older animals. No anti-
inflammatory effect of the CBDext was observed at any age. Data are expressed as mean values – SEM.
*p < 0.05, **p < 0.01, and ***p < 0.001, compared with WT. Aif1, gene coding for IBA1; Gfap, gene coding
for GFAP; Il1B, gene coding for IL1beta; Il6, gene coding for IL6; Tnfa, gene coding for TNFalpha; IL, interleukin.





















































cortex (Fig. 6D) but a significant increase in the hippo-
campal levels of IBA1 of malin KO mice treated with ve-
hicle ( p < 0.05) or CBDext ( p < 0.05) when compared
with WT animals (Fig. 6B).
We also quantified the gene expression of various
components of inflammatory signaling, including IBA1,
GFAP, TNF-a, IL-1b, IL-6, and IL-10. As expected,
malin KO mice treated from 10 months of age expressed
higher levels of all the inflammatory signaling compo-
nents when compared with WT mice in both the cortex
and hippocampus, but no significant effect of treatment
was observed in any case (Fig. 7B, D). At earlier stages,
such differences were restricted to GFAP in the cortex
and hippocampus and IL-1b in the cortex (Fig. 7A, C).
Specific details about statistical analysis of the gene ex-
pression of inflammatory signaling components are in-
cluded in Table 2. These results confirm the previously
described increase of the inflammatory response during
disease progression in this LD model,14 but they fail to
demonstrate an anti-inflammatory effect of the CBDext
at any age.
Anticonvulsant properties
of the CBD-enriched extract
Finally, we evaluated the hypothetical anticonvulsant
properties of the CBDext in malin KO mice. This
animal model does not replicate the severe epileptic
phenotype occurring in LD patients from early child-
hood, but it does manifest sporadic seizures from 15
months of age. Moreover, we observed that malin
KO mice have greater susceptibility to pilocarpine-
induced seizures.
Thus, we tested the anticonvulsant properties of the
CBDext in malin KO and WT mice aged 16 months by
using a submaximal dose of pilocarpine to induce sei-
zures. Two-way ANOVA revealed a significant geno-
type effect [F(1,16) = 11.455, p < 0.01], but no treatment
effect [F(1,16) = 0.649, not significant (N.S.)] or interaction
between the two factors [F(1,16) = 0.234, N.S.], in the score
calculated for pilocarpine-induced seizures (Fig. 8A).
Subsequent Tukey’s post hoc test indicated that malin
KO mice exhibited a higher score than WT littermates
in both the vehicle ( p < 0.05) and CBD-treated groups
Table 2. Statistical Details of the Inflammatory Signaling Components Gene Expression in Cortex and Hippocampus
of Malin Knockout Mice Treated During 8 Weeks from 4 or 10 Months of Age with Cannabidiol-Enriched Extract or Vehicle











Two-way ANOVA (treatment from 4 months of age)
Aif1 F(1,18) = 3.667, N.S. F(1,18) = 0.001, N.S. F(1,18) = 0.321, N.S. — — — —
Gfap F(1,18) = 25.130, p < 0.001 F(1,18) = 0.030, N.S. F(1,18) = 1.592, N.S. p < 0.001 p < 0.05 — —
Il1B F(1,16) = 28.910, p < 0.001 F(1,16) = 4.040, N.S. F(1,16) = 4.833, p < 0.05 p < 0.01 p < 0.001
Il6 F(1,18) = 2.659, N.S. F(1,18) = 0.415, N.S. F(1,18) = 0.014, N.S. — — — —
Tnfa F(1,18) = 3.516, N.S. F(1,18) = 3.189, N.S. F(1,18) = 2.533, N.S. — — — —
Two-way ANOVA (treatment from 10 months of age)
Aif1 F(1,12) = 35.340, p < 0.001 F(1,12) = 0.062, N.S. F(1,12) = 0.870, N.S. p < 0.01 p < 0.01 — —
Gfap F(1,13) = 27.400, p < 0.001 F(1,13) = 0.152, N.S. F(1,13) = 0.287, N.S. p < 0.01 p < 0.05 — —
Il1B F(1,11) = 6.010, p < 0.05 F(1,11) = 0.262, N.S. F(1,11) = 0.046, N.S. N.S. p < 0.05 — —
Il6 F(1,12) = 29.980, p < 0.001 F(1,12) = 0.544, N.S. F(1,12) = 1.869, N.S. p < 0.05 p < 0.01 — —
Tnfa F(1,12) = 5.611, p < 0.05 F(1,12) = 0.373, N.S. F(1,12) = 0.074, N.S. N.S. p < 0.01 — —
Cortex
Two-way ANOVA (treatment from 4 months of age)
Aif1 F(1,19) = 0.746, N.S. F(1,19) = 6.166, p < 0.05 F(1,19) = 0.004, N.S. — — N.S. N.S.
Gfap F(1,20) = 7.670, p < 0.05 F(1,20) = 0.218, N.S. F(1,20) = 0.125, N.S. p < 0.01 N.S. — —
Il1B F(1,20) = 2.240, N.S. F(1,20) = 0.053, N.S. F(1,20) = 0.133, N.S. — — — —
Il6 F(1,20) = 0.076, N.S. F(1,20) = 0.260, N.S. F(1,20) = 1.734, N.S. — — — —
Tnfa F(1,19) = 0.001, N.S. F(1,19) = 2.035, N.S. F(1,19) = 1.231, N.S. — — — —
Two-way ANOVA (treatment from 10 months of age)
Aif1 F(1,20) = 7.698, p < 0.05 F(1,20) = 0.055, N.S. F(1,20) = 0.072, N.S. p = 0.06 N.S. — —
Gfap F(1,20) = 19.288, p < 0.001 F(1,20) = 0.090, N.S. F(1,20) = 0.096, N.S. p < 0.01 p < 0.05 — —
Il1B F(1,20) = 8.525, p < 0.01 F(1,20) = 0.204, N.S. F(1,20) = 0.193, N.S. p = 0.06 p = 0.06 — —
Il6 F(1,20) = 9.155, p < 0.01 F(1,20) = 0.457, N.S. F(1,20) = 0.694, N.S. p = 0.06 p < 0.05 — —
Tnfa F(1,20) = 6.323, p < 0.05 F(1,20) = 0.776, N.S. F(1,20) = 0.645, N.S. p < 0.05 N.S. — —
Two-way ANOVA with genotype and treatment as between-subjects factors was applied for the analysis of the gene expression levels of several
components of the inflammatory signaling. When one factor or interaction between factors was significant, comparisons between groups were per-
formed by Tukey’s post hoc test. See the Materials and Methods section for details.
CBDext, CBD-enriched extract.





















































( p = 0.06). Higher susceptibility to pilocarpine in malin
KO mice was also revealed by the increased mortality as-
sociated with the acute administration of a submaximal
dose of pilocarpine when compared with WT mice
[v2(1) = 5.495, p < 0.05] (Fig. 8B).
It is worthy to note that the dose of CBD used here
(35 mg/kg) was significantly lower than the ones used
to reveal the anticonvulsant properties of CBD in an an-
imal model of Dravet syndrome (100–200 mg/kg),20 sug-
gesting that testing higher doses of CBD might result in
better results in our animal model. However, the fact that
CBDext pretreatment, even at the low dose evaluated in
this study, tends to increase the severity of pilocarpine ef-
fects in terms of lethality (Fig. 8B) [v2(1) = 1.978, p = 0.15]
dampens the interest to test higher doses of CBDext in
malin KO mice.
These results, although unexpected, are not com-
pletely surprising, since recent studies have revealed
that up to 15.4% of the patients enrolled in a study to
evaluate long-term safety, tolerability, and efficacy of
purified CBD in children with refractory epilepsy
reported an increase in the number of seizures after ex-
posure to doses of CBD equivalent to that included
in this study.21 Moreover, considering the complexity
of endocannabinoid signaling in epilepsy,22 we cannot
rule out that other cannabinoids present in the natural
extract might contribute to the apparent increased le-
thality observed in CBDext-treated mice after pilocar-
pine exposure.
Conclusions
In summary, this study reveals that the ECS might play
a role in LD since the levels of the main cannabinoid
receptors are altered during the disease progression
in malin KO mice. Moreover, a CBD-enriched ex-
tract partially reduces the dementia-like phenotype
in these animals. However, this extract does not halt
the increased vulnerability to epileptic seizures exhibited
by this animal model of such a life-threatening disease.
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FIG. 8. Increased susceptibility to pilocarpine-induced seizures in malin KO with respect to WT mice. (A)
Score obtained 1 h after the administration of a submaximal dose of pilocarpine (250 mg/kg, i.p.) according to
this scale: (1) tremor; (2) single myoclonic jerks; (3) clonus; (4) one tonic-clonic seizure; (5) two seizures; (6) three
or more seizures, and (7) death, or status epilepticus. No significant difference due to the treatment (CBDext:
98.5 mg/kg/day, containing 35 mg/kg/day of CBD and 4.8 mg/kg/day of D9-THC, among other minor
cannabinoids) was observed. Data are expressed as the mean values – SEM. *p < 0.05, p = 0.06 compared with
WT after pilocarpine treatment. (B) Mortality after pilocarpine injection was increased in malin KO mice when
compared with WT. CBDext pretreatment tends to increase the lethality of pilocarpine in mice, although no
statistical difference due to the treatment was observed.
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Abbreviations Used
ANOVA¼ analysis of variance
CBD¼ cannabidiol
CBDext¼CBD-enriched extract
ECS¼ endogenous cannabinoid system
FAAH¼ fatty acid amide hydrolase






PSD-95¼ postsynaptic density protein-95
THC¼ tetrahydrocannabinol
TRPV1¼ transient receptor potential vanilloid-1
WT¼wild-type
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